If biotech had a Mount Rushmore, whose heads would you chisel in the granite?
Who goes on a biotech Mount Rushmore is probably a debate best had while sitting on barstools, but offer your own lineup in the comments.
If someone sculpted a Mount Rushmore of biotech CEOs, who’d be on it?
The question struck me last week as I was considering the legacy of Vertex Pharma CEO Jeff Leiden upon his retirement. Leiden’s eight-year run at Vertex was a boon for cystic fibrosis patients and shareholders. His tenure could be viewed as record-breaking, but was it historic enough to cast his visage in granite?
Let’s table the Leiden decision for a moment and step back to discuss the criteria for the Mount Rushmore of biotech CEOs. No such monument exists, obviously, but it’s still fun to argue
